BioReliance Launches Global Sales and Marketing Organization
Diana Morgan, Ph.D. Named Vice President of the Worldwide Group
ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- BioReliance Corporation (Nasdaq: BREL) announced today that it has launched a global sales and marketing organization, now offering its biologics testing and manufacturing services on a comprehensive basis to clients around the world. This reorganization follows BioReliance's acquisition of Q-One Biotech, headquartered in Glasgow, Scotland, and represents a major step in implementing the Company's post-acquisition strategy of serving its international client base with global service offerings and support. The move integrates a sales and marketing function that had been segmented regionally. As a newly appointed vice president, Diana Morgan, Ph.D., 50, will now lead the global sales and marketing organization from her offices in Glasgow, Scotland and Rockville, Maryland. Dr. Morgan most recently had been the Director of Sales for European Testing, Development and Manufacturing for BioReliance. She joined the Company in 1994 following a successful career spanning 14 years at The Beatson Institute for Cancer Research, where she gained her doctorate, followed by a number of years as Laboratory Manager at the Leukemia Research Fund Laboratory established by Professor David Onions, one of the founders of Q-One Biotech. Key personnel from both the former Q-One and BioReliance organizations join her team in this integration. Capers W. McDonald, President and CEO, said, "This reorganization is part of creating a more capable and global service enterprise. We are delighted that Dr. Morgan will be leading us beyond the additive combination of our two organizations to better serve the global marketplace. With approximately half of our business now originating outside North America, we are fortunate to have someone of Dr. Morgan's international experience in this newly created position. We therefore view the initial costs of globalization -- relating both to the acquisition of Q-One and the reorganization of our sales and marketing -- as important investments that position us to provide a new level of service in our competitive marketplace." In accepting her new role, Dr. Morgan commented, "This opportunity is of tremendous value to our current and prospective clients. Q-One has been an outstanding service provider, and they are already complementing our growing U.S. and U.K. operations. "Quality, science and services that can be relied upon worldwide are key parts of our strategy and a continuing pledge to our clients going forward. These capabilities are continuing at all sites -- in Glasgow and Stirling in the U.K., in Worcester and Rockville in the U.S., and in Heidelberg in Germany." Dr. Morgan continued, "The combination of BioReliance and Q-One has created an expanded, more vital service company. We now provide extended resources and know-how to serve the needs of our customers. We are increasing our range of services, since we plan the continued availability of Q-One assays. We enjoy considerably greater capacities for scheduling client work, enhancing timeliness while maintaining quality. We will continue both custom and standard services, and can better source required services in the most cost effective manner possible. The combination also will enhance multi-site backup capabilities for many services." The Company also announced that Ronald Baker, former Vice President of Sales and Marketing in the U.S., has left the Company to pursue other opportunities. About BioReliance BioReliance Corporation is a leading, global contract service organization providing integrated testing, development and manufacturing services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company believes it is the largest provider of outsourcing services focused on the expanding biologics sector of the pharmaceutical industry. Forward-Looking Statements Certain statements made in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance, or achievements, and may contain the words "believe," "anticipate," "confident," "expect," "estimate," "project," "will be," "will continue," "will likely result," or similar words or phrases. Comments such as those with respect to BioReliance's ability to integrate effectively and efficiently the operations of Q-One Biotech, constitute forward-looking statements. As and when made, management believes that these forward-looking statements are reasonable. BioReliance undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from the forward-looking statements. Risks and uncertainties are detailed from time to time in reports filed by BioReliance with the Securities and Exchange Commission, including in its Forms 10-K and 10-Q. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.
SOURCE BioReliance Corporation
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.